STOCK TITAN

Globus Medical (NYSE: GMED) director exercises options, sells 25,000 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Globus Medical director David D. Davidar reported an exercise-and-sell transaction in Class A common stock. He exercised stock options for 25,000 shares at $26.27 per share and sold 25,000 shares in an open-market transaction at a weighted average price of $80.7629 per share.

Following these moves, Davidar directly holds 510,175 shares of Class A common stock. In addition, a family irrevocable trust established on August 6, 2009 holds 165,967 shares for the benefit of his spouse and children, with his spouse serving as trustee.

Positive

  • None.

Negative

  • None.
Insider Davidar David D
Role null
Sold 25,000 shs ($2.02M)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy Class A Common Stock) 25,000 $0.00 --
Exercise Class A Common Stock 25,000 $26.27 $657K
Sale Class A Common Stock 25,000 $80.7629 $2.02M
holding Class A Common Stock -- -- --
Holdings After Transaction: Stock Option (Right to Buy Class A Common Stock) — 0 shares (Direct, null); Class A Common Stock — 535,175 shares (Direct, null); Class A Common Stock — 165,967 shares (Indirect, By Davidar Family Irrevocable Trust U/A 8/6/09)
Footnotes (1)
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at a price range of $80.59 - $80.92, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares at each separate price within the range set forth in footnote (1) of this Form 4. These shares are held in a trust for the benefit of the reporting person's spouse and children. The reporting person's spouse is trustee of the trust. These options were granted on January 30, 2017 and are fully vested.
Shares sold 25,000 shares Class A Common Stock open-market sale on 2026-06-05
Sale price (weighted average) $80.7629 per share Open-market sale price range $80.59–$80.92
Options exercised 25,000 shares Stock option exercise on 2026-06-05
Option exercise price $26.27 per share Stock option (Right to Buy Class A Common Stock)
Direct holdings after transactions 510,175 shares Class A Common Stock directly owned after 2026-06-05
Indirect trust holdings 165,967 shares Held by Davidar Family Irrevocable Trust U/A 8/6/09
Derivative position remaining 0 options Stock option balance after 25,000-share exercise
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Stock Option (Right to Buy Class A Common Stock) financial
"security_title: Stock Option (Right to Buy Class A Common Stock)"
irrevocable trust financial
"By Davidar Family Irrevocable Trust U/A 8/6/09"
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.
fully vested financial
"These options were granted on January 30, 2017 and are fully vested."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Davidar David D

(Last)(First)(Middle)
VALLEY FORGE BUSINESS CENTER
2560 GENERAL ARMISTEAD AVENUE

(Street)
AUDUBON PENNSYLVANIA 19403

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
GLOBUS MEDICAL INC [ GMED ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Common Stock06/05/2026M25,000A$26.27535,175D
Class A Common Stock06/05/2026S25,000D$80.7629(1)510,175D
Class A Common Stock165,967IBy Davidar Family Irrevocable Trust U/A 8/6/09(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy Class A Common Stock)$26.2706/05/2026M25,000 (3)01/30/2027Class A Common Stock25,000$00D
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at a price range of $80.59 - $80.92, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares at each separate price within the range set forth in footnote (1) of this Form 4.
2. These shares are held in a trust for the benefit of the reporting person's spouse and children. The reporting person's spouse is trustee of the trust.
3. These options were granted on January 30, 2017 and are fully vested.
/s/ Kelly G. Huller, Attorney-in-Fact06/09/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Globus Medical (GMED) director David D. Davidar report in this Form 4?

David D. Davidar reported exercising stock options for 25,000 Globus Medical shares at $26.27 and selling 25,000 shares in an open-market transaction at a weighted average price of $80.7629, reflecting a routine exercise-and-sell pattern.

How many Globus Medical (GMED) shares did Davidar sell and at what price?

He sold 25,000 shares of Globus Medical Class A common stock in the open market at a weighted average price of $80.7629 per share, with individual trades occurring within a price range of $80.59 to $80.92, as disclosed in the footnotes.

What stock options did Davidar exercise in this Globus Medical (GMED) filing?

Davidar exercised stock options covering 25,000 shares of Globus Medical Class A common stock at an exercise price of $26.27 per share. The options were originally granted on January 30, 2017 and were fully vested at the time of exercise, according to the disclosure.

What are Davidar’s direct and indirect Globus Medical (GMED) holdings after the transactions?

After the reported transactions, Davidar directly holds 510,175 shares of Globus Medical Class A common stock. Additionally, a family irrevocable trust for his spouse and children holds 165,967 shares, which are reported as indirectly owned through that trust arrangement.

How are the trust-held Globus Medical (GMED) shares structured for Davidar’s family?

The filing states that 165,967 Globus Medical shares are held in a family irrevocable trust created on August 6, 2009 for the benefit of Davidar’s spouse and children. His spouse serves as trustee, and these shares are reported as indirectly owned by Davidar.

Were the Globus Medical (GMED) share sales in this Form 4 made at a single price?

No. The Form 4 explains that the reported sale price of $80.7629 is a weighted average. The 25,000 shares were sold in multiple transactions at prices ranging from $80.59 to $80.92, and detailed trade breakdowns are available on request.